Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design
about
Rational approaches to improving selectivity in drug designIntegrins Influence the Size and Dynamics of Signaling Microclusters in a Pyk2-dependent MannerA conserved mechanism of autoinhibition for the AMPK kinase domain: ATP-binding site and catalytic loop refolding as a means of regulationDual kinase-bromodomain inhibitors for rationally designed polypharmacologyAffinity reagents that target a specific inactive form of protein kinases.Targeting Pyk2 for therapeutic interventionEvidence for the involvement of proline-rich tyrosine kinase 2 in tyrosine phosphorylation downstream of protein kinase A activation during human sperm capacitation.Role of focal adhesion tyrosine kinases in GPVI-dependent platelet activation and reactive oxygen species formation.A role for the protein tyrosine phosphatase CD45 in macrophage adhesion through the regulation of paxillin degradation.DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts.AG490 and PF431396 Sensitive Tyrosine Kinase Control the Population Heterogeneity of Basal STAT1 Activity in Ube1l Deficient CellsAn in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2.Pyk2 and Megakaryocytes Regulate Osteoblast Differentiation and Migration Via Distinct and Overlapping Mechanisms.Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic depolarization-induced vascular smooth muscle contraction.Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).Dynamin and PTP-PEST cooperatively regulate Pyk2 dephosphorylation in osteoclasts.Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells.A role for the tyrosine kinase Pyk2 in depolarization-induced contraction of vascular smooth muscle.Focal adhesion kinases in adhesion structures and disease.Pyk2 inhibition promotes contractile differentiation in arterial smooth muscle.Survey of the 2009 commercial optical biosensor literature.Up-regulation of PYK2/PKCα-dependent haem oxygenase-1 by CO-releasing molecule-2 attenuates TNF-α-induced lung inflammation.FAK inhibitors in Cancer, a patent review.Kinase-targeted cancer therapies: progress, challenges and future directions.Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.A role for focal adhesion kinase in facilitating the contractile responses of murine gastric fundus smooth muscles.PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein
P2860
Q26865357-7C621CCB-7B78-40DB-AC35-C0545248D38CQ27314180-3A25D7C1-6D21-48E0-9816-7716EA2C6E78Q27659450-9E1B120A-7498-4AED-9B4F-23D7549AB47EQ27681935-C7A435D0-7CB2-4D12-B2E2-4DE318D6FDE5Q33853940-EBF74CF4-AB1D-4004-8BE5-931776FB34C7Q34146883-92677CBF-F3CA-451A-A641-82081861C5E1Q34406911-1F10FE43-6BC7-42C3-8AEA-568265226311Q34557479-235B0539-F189-417F-810B-D82349EE3279Q34923837-52A1E0FA-F45E-4A8B-88A9-4D824A3CF69CQ34992813-8DDB9362-2C0E-4CF8-BD08-99E2FFE25399Q36007028-8F1F743A-F30A-47D8-8FB1-25D83DC1E7BCQ36079962-3D46A345-9451-44D0-996A-8993A57EDA06Q36390162-7A5EE933-28CD-4067-BE1B-28DEEF443DF0Q36767926-D8BD4432-4A58-49B0-A6D4-8147280BAF68Q37750751-068A6395-8ACC-4DD1-8A85-F4BF017CEC1CQ38239003-2FB4C55B-AC9F-48BF-8D6E-BDD4666188A6Q38543448-B301344E-392B-48D1-9EC4-6B8115B27152Q39025426-BB80D5E7-38FA-47C9-A911-542306E796F6Q39395485-4D69D8BE-A87E-4366-888E-FD8085EEE45AQ39685403-4F51EE32-7A94-4626-A3F9-166BC34113BFQ40402700-87ADF265-728B-4E17-9DCC-84FB138E73A9Q42257455-E4E7C0B9-9634-4246-9453-4EECE9F11A1DQ42503512-ECA95DFF-F2A8-4414-8226-FFAFFE21CCF4Q45399191-EE544E79-E05E-4363-8DC9-7592F00F79A2Q47400676-5DC12B04-B6A1-4C77-9FDC-EB6A06B533F4Q47797785-6BFE5A7F-1F4F-49CC-A279-E0F3496B293AQ49887882-6EF35817-72FE-47DA-B10D-DE022BA8DBB0Q52144637-4D520009-3B43-487C-AD7E-F2CA2AFF922FQ52661267-4F7D1B0F-9AAE-4231-805D-4BA65124E876Q58700618-6DBDE0CD-96FB-46B1-A4C4-79EB1F65D81B
P2860
Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Structural Characterization of ...... n and Enables Inhibitor Design
@ast
Structural Characterization of ...... n and Enables Inhibitor Design
@en
Structural Characterization of ...... n and Enables Inhibitor Design
@nl
type
label
Structural Characterization of ...... n and Enables Inhibitor Design
@ast
Structural Characterization of ...... n and Enables Inhibitor Design
@en
Structural Characterization of ...... n and Enables Inhibitor Design
@nl
prefLabel
Structural Characterization of ...... n and Enables Inhibitor Design
@ast
Structural Characterization of ...... n and Enables Inhibitor Design
@en
Structural Characterization of ...... n and Enables Inhibitor Design
@nl
P2093
P2860
P3181
P356
P1476
Structural Characterization of ...... n and Enables Inhibitor Design
@en
P2093
Anil Mistry
Arthur D Brosius
Boris A Chrunyk
Daniel P Walker
David Cunningham
Gary E Aspnes
Jeanne S Chang
Leonard Buckbinder
Matt Griffor
P2860
P304
P3181
P356
10.1074/JBC.M809038200
P407
P577
2009-05-08T00:00:00Z